Table 1. Demographic, pre-operative, and clinicopathologic characteristics by treatment group.
SF, surgery first; SMNT, single modality neoadjuvant therapy; TNT, total neoadjuvant therapy; BMI, body mass index.
| Overall cohort (N=358) | SF (N=168) | SMNT (N=111) | TNT (N=79) | ||
|---|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | p-value | |
| Gender | |||||
| Female | 174 (48.6) | 85 (50.6) | 56 (50.5) | 33 (41.8) | 0.40 |
| Male | 184 (51.4) | 83 (49.4) | 55 (49.5) | 46 (58.2) | |
| Race | |||||
| White | 329 (91.9) | 161 (95.8) | 100 (90.1) | 68 (86.1) | 0.053 |
| Black | 18 (5.0) | 4 (2.4) | 6 (5.4) | 8 (10.1) | |
| Other | 11 (3.1) | 3 (1.8) | 5 (4.5) | 3 (3.8) | |
| Age at diagnosis, years | |||||
| Median [IQR] * | 68 [61, 75] | 70 [61.5, 76] | 68 [61, 75] | 67 [59, 73] | 0.079 |
| ECOG | |||||
| 0 | 262 (78.2) | 125 (82.2) | 82 (78.1) | 55 (70.5) | 0.32 |
| 1 | 67 (20.0) | 25 (16.5) | 21 (20.0) | 21 (26.9) | |
| 2 | 6 (1.8) | 2 (1.3) | 2 (1.9) | 2 (2.6) | |
| Missing | 23 | 16 | 6 | 1 | |
| Hypertension | |||||
| Yes | 201 (56.8) | 89 (53.0) | 62 (57.9) | 50 (63.3) | 0.31 |
| No | 153 (43.2) | 79 (47.0) | 45 (42.1) | 29 (36.7) | |
| Missing | 4 | 0 | 4 | 0 | |
| Smoker | |||||
| Yes | 146 (41.4) | 62 (36.9) | 50 (47.2) | 34 (43.0) | 0.23 |
| No | 207 (58.6) | 106 (63.1) | 56 (52.8) | 45 (57.0) | |
| Missing | 5 | 0 | 5 | 0 | |
| Diabetes Mellitus | |||||
| Yes | 123 (34.8) | 62 (36.9) | 36 (33.6) | 25 (31.6) | 0.70 |
| No | 231 (65.2) | 106 (63.1) | 71 (66.4) | 54 (68.4) | |
| Missing | 4 | 0 | 4 | 0 | |
| Coronary.Artery Disease | |||||
| Yes | 109 (30.8) | 52 (31.0) | 23 (21.5) | 34 (43.0) | 0.007 |
| No | 245 (69.2) | 116 (69.0) | 84 (78.5) | 45 (57.0) | |
| Missing | 4 | 0 | 4 | 0 | |
| Hyperlipidemia | |||||
| Yes | 110 (33.5) | 41 (26.3) | 32 (32.7) | 37 (50.0) | 0.002 |
| No | 218 (66.5) | 115 (73.7) | 66 (67.4) | 37 (50.0) | |
| Missing | 30 | 12 | 13 | 5 | |
| BMI ≥ 25 | |||||
| Yes | 188 (66.2) | 92 (71.3) | 44 (55.7) | 52 (68.4) | 0.065 |
| No | 96 (33.8) | 37 (28.7) | 35 (44.3) | 24 (31.6) | |
| Missing | 74 | 39 | 32 | 3 | |
| NCCN Resectability Classification | |||||
| Resectable | 155 (46.8) | 121 (79.1) | 22 (21.6) | 12 (15.8) | <0.001 |
| Borderline | 144 (43.5) | 29 (19.0) | 61 (59.8) | 54 (71.1) | |
| Locally advanced | 32 (9.7) | 3 (2.0) | 19 (18.6) | 10 (13.2) | |
| Missing | 27 | 15 | 9 | 3 | |
| Clinical Stage | |||||
| 0 | 5 (1.5) | 5 (3.4) | 0 (0.0) | 0 (0.0) | <0.001 |
| IA | 40 (12.4) | 32 (21.6) | 5 (5.0) | 3 (4.0) | |
| IB | 133 (41.1) | 66 (44.6) | 39 (38.6) | 28 (37.3) | |
| IIA | 31 (9.6) | 13 (8.8) | 14 (13.9) | 4 (5.3) | |
| IIB | 59 (18.2) | 25 (16.9) | 19 (18.8) | 15 (20.0) | |
| III | 56 (17.3) | 7 (4.7) | 24 (23.8) | 25 (33.3) | |
| Missing | 34 | 20 | 10 | 4 | |
| Initial CA19–9 | |||||
| N, median | 309190 | 151194 | 82194 | 76188 | 0.93 |
| IQR * | [50.1, 672] | [61.9, 545] | [52.1, 707] | [33, 1062.5] | |
| Post Neoadjuvant CA 19–9 | |||||
| N, median | 7039.9 | 7537 | 0.35 | ||
| IQR * | [11, 178] | [12.5, 68] |
*
Interquartile range given as [25th percentile,75th percentile]